Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab

被引:5
|
作者
Schargus, Marc [1 ,2 ]
Kopp, Katharina Tatjana [3 ]
Helbig, Constanze [4 ]
Frings, Andreas [1 ]
Winter, Gerhard [3 ]
机构
[1] Heinrich Heine Univ Dusseldorf, Dept Ophthalmol, Moorenstr 5, D-40225 Dusseldorf, Germany
[2] Asklepios Hosp Nord Heidberg, Dept Ophthalmol, Hamburg, Germany
[3] Ludwig Maximilians Univ Munchen, Dept Pharm Pharmaceut Technol & Biopharmaceut, Munich, Germany
[4] Coriolis Pharma Res GmbH, Martinsried, Germany
来源
关键词
aflibercept; bevacizumab; brolucizumab; contamination; protein particles; silicone oil; intravitreal injection; INTRAOCULAR-PRESSURE; RANIBIZUMAB; INJECTION; TRAP;
D O I
10.1167/tvst.10.9.21
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated. Methods: Commercially available ready-to-use aflibercept and brolucizumab glass syringes, vials containing bevacizumab (off-label use in ophthalmology), and repackaged ready-to-use plastic syringes containing bevacizumab were tested without filtration. Total visible, subvisible, and nanoparticles numbers and size distributions were quantified using light obscuration, flow imaging, resonant mass measurement (RMM), tunable resistive pulse sensing, and dynamic light scattering. Results: Repackaged bevacizumab showed overall low particle numbers, aflibercept showed high numbers of micrometer sized particles but low nanoparticle numbers, brolucizumab showed low to moderate numbers of micrometer sized particles but high nanoparticle numbers. RMM measurements identified particles in the nanometer range as either proteinaceous or silicon oil; the nature of the other particles was not further evaluated. Conclusions: Repackaged bevacizumab shows no inferior particle quality compared to ready-to-use products. It is relevant to study nanoparticle load of the products as the micrometer-sized particle numbers do not in all cases correlate to nanoparticle counts. Particularly for the high concentration product Beovu (brolucizumab), high nanoparticle numbers were found despite low numbers of micrometer sized particles. Silicone oil droplets did not account for high particle numbers as the measured numbers were low. Translational Relevance: Different side effects are registered in different frequencies with different intravitreal anti-VEGF-drugs and syringes, which are applied by injection by small 30G needles through the sclera directly to the intravitreal cavity. The study of nanoparticles and silicone oil droplets may be able to contribute to narrowing down the causes.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD [Intravitreale anti-VEGF-therapie mit bevacizumab bei neovaskulärer AMD]
    Schaal K.B.
    Engler C.
    Schütt F.
    Scheuerle A.
    Dithmar S.
    Der Ophthalmologe, 2008, 105 (6): : 538 - 543
  • [22] Intravitreal anti-VEGF bevacizumab (Avastin) for external beam-related radiation retinopathy
    Finger, Paul T.
    Mukkamala, Sri Krishna
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2011, 21 (04) : 446 - 451
  • [23] Anti-VEGF switch therapy from bevacizumab to aflibercept in radiation retinopathy secondary to uveal melanoma
    Srivastava, Ojas
    Weis, Ezekiel
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [24] Sustained anti-VEGF activity of aflibercept (Eylea™) after storage in polycarbonate syringes used for intravitreal injection: a pathway to safety and efficiency in high volume clinics providing intravitreal therapy.
    Han, Dennis P.
    Skumatz, Christine
    Besharse, Joseph C.
    Kassem, Iris S.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [25] Preservation of Bevacizumab Anti-VEGF Bioactivity and Monomeric Structure During Processing into a Sustained Release Bevacizumab Intravitreal Depot
    Guedez, Sarah
    Blizzard, Charles D.
    Wyand, Allison
    Wittbold, Jennifer
    Elhayek, Rami F.
    Vanslette, Andrew
    Jarrett, Peter K.
    Driscoll, Arthur
    Sawhney, Amar
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [26] Fluctuation Speed as a New Criterion to Evaluate the Efficiency of Intravitreal Anti-VEGF Drugs
    Kaya, Abdullah
    OPHTHALMOLOGICA, 2016, 235 (04) : 242 - 242
  • [27] Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
    Garcia-Quintanilla, Laura
    Luaces-Rodriguez, Andrea
    Gil-Martinez, Maria
    Mondelo-Garcia, Cristina
    Maronas, Olalla
    Mangas-Sanjuan, Victor
    Gonzalez-Barcia, Miguel
    Zarra-Ferro, Irene
    Aguiar, Pablo
    Otero-Espinar, Francisco J.
    Fernandez-Ferreiro, Anxo
    PHARMACEUTICS, 2019, 11 (08)
  • [28] Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept
    Hong, Hye Kyoung
    Park, Young Joo
    Kim, Duk Ki
    Ryoo, Na-Kyung
    Ko, You-Jin
    Park, Kyu Hyung
    Kim, Ho Min
    Woo, Se Joon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (13)
  • [29] Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review
    Uzzan, Joel
    Mapani, Adam
    Cox, Oliver
    Bagijn, Marloes
    Saffar, Insaf
    OPHTHALMOLOGY AND THERAPY, 2024, 13 (09) : 2445 - 2465
  • [30] Treatment of Retinal Angiomatous Proliferation with Intravitreal Anti-VEGF Drugs in Real Life Practice
    Parodi, Maurizio Battaglia
    Donati, Simone
    Azzolini, Claudio
    Pece, Alfredo
    Bottoni, Ferdinando
    Danzi, Paola
    Introini, Ugo
    Pucci, Vincenzo
    Semeraro, Francesco
    Viola, Francesco
    Luce, Progetto
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)